FDMT - NASDAQ
4D Molecular Therapeutics, Inc.
$9.53
+2.8%4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
At a Glance
Live Snapshot4D Molecular Therapeutics, Inc. Management Team
Dr. An Song Ph.D.
Chief Development Officer
Mr. Uneek Mehra
Chief Financial & Business Officer
Compensation
$823,899
Dr. Scott P. Bizily J.D., Ph.D.
Chief Legal Officer & Corporate Secretary
Dr. Robert Y. Kim M.B.A., M.D.
Chief Medical Officer
Compensation
$704,843
Dr. Noriyuki Kasahara M.D., Ph.D.
Chief Scientific Officer
Compensation
$201,288
Ms. Theresa Janke
Co-Founder & Chief of Staff
Compensation
$652,315
Dr. David H. Kirn M.D.
Co-Founder, Chief Executive Officer & Director
Compensation
$1,009,003
Dr. John F. Milligan Ph.D.
Executive Chairman
Compensation
$150,000
Dr. Fariborz Kamal Ph.D.
President & Chief Operating Officer
Compensation
$734,607
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.
Senior Vice President & Therapeutic Area Head of Pulmonology
4D Molecular Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $63K worth of FDMT shares, with no buying activity reported.
3 Months
0
0.00
2.0K
19.95K
-20K
-$20K
3-6 Months
0
0.00
1.7K
18.51K
-19K
-$19K
6-9 Months
0
0.00
2.7K
24.35K
-24K
-$24K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Bizily Scott
Officer: Chief Legal Officer
$42K
Kirn David
Director, Officer: See Remarks
$19K
Gupta Ashoo
Officer: Vp, Finance And Controller
$1K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $63K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
FDMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | May 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 12, 2023 | May 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | May 23, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 06, 2021 | May 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.